View More Recent Stories

Mar 18, 2021 07:00AM RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Mar 11, 2021 07:00AM RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021
Mar 5, 2021 07:00AM RedHill to Present at Upcoming Conferences in March
Mar 2, 2021 09:06AM ObvioHealth and RedHill Biopharma Launch First in Kind Remote COVID-19 Therapy Trial Incorporating Highest Level of At-home Patient Monitoring to Date
Feb 23, 2021 07:09AM UPDATE: RedHill Biopharma (RDHL) Reports Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
Feb 23, 2021 07:03AM RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
Feb 18, 2021 07:00AM RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204
Feb 17, 2021 07:34AM Redhill Biopharma Ltd (REDIF) Reports First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107
Feb 17, 2021 07:00AM RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107
Feb 9, 2021 07:00AM RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences
Jan 29, 2021 07:05AM Redhill Biopharma (REDIF) Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
Jan 29, 2021 07:00AM RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
Jan 28, 2021 07:27AM RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals
Jan 11, 2021 07:00AM RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D
Jan 6, 2021 07:00AM RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease
Dec 22, 2020 07:01AM RedHill Biopharma (RDHL) Reports Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue
Dec 22, 2020 07:00AM RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue
Dec 11, 2020 08:05PM Annual Changes to the Nasdaq Biotechnology Index
Sep 23, 2020 07:09AM Veeva Systems (VEEV), Bioforum Report Collaboration with RedHill Biopharma (RDHL) o Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data
Sep 23, 2020 07:03AM Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data
Jun 15, 2015 03:06PM Notable 52-Week Highs and Lows 6/15: (AIG) (CYBR) (RDHL) High; (MU) (TWTR) (ONDK) Low
View More Recent Stories